

Anti-inflammatory and Cytotoxic Neoflavonoids and Benzofurans from *Pterocarpus santalinus*

Shou-Fang Wu,[†] Fang-Rong Chang,^{*,†,‡} Sheng-Yang Wang,[§] Tsong-Long Hwang,[⊥] Chia-Lin Lee,^{†,||} Shu-Li Chen,[†] Chin-Chung Wu,[†] and Yang-Chang Wu^{*,†,||,▽}

[†]Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 807, Taiwan, Republic of China

[‡]Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, Republic of China

[§]Department of Forestry, National Chung-Hsing University, Taichung 402, Taiwan, Republic of China


[⊥]Graduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan, Republic of China

^{||}Natural Medicinal Products Research Center and Center for Molecular Medicine, China Medical University Hospital, Taichung 40402, Taiwan, Republic of China

[▽]Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan, Republic of China

S Supporting Information

ABSTRACT: Five new benzofurans, pterolinuses A–E (1–5), six new neoflavonoids, pterolinuses F–J (8–13), and five known compounds (6, 7, 14–16) were isolated from an extract of *Pterocarpus santalinus* heartwood. All new structures were elucidated by spectroscopic methods, and configurations were confirmed by CD spectral data and optical rotation values. The isolates were evaluated for anti-inflammatory and cytotoxic activities. Six compounds (1, 2, 4, 6, 7, and 15) showed significant inhibition in at least one anti-inflammatory assay. Compound 2 showed the best selective effect against superoxide anion generation in human neutrophils with, an IC₅₀ value of 0.19 μg/mL, and was 6.2-fold more potent than the positive control LY294002. Compound 14 showed the highest cytotoxicity against Ca9-22 cancer cells, with an IC₅₀ value of 0.46 μg/mL.



Pterocarpus santalinus L. (Fabaceae), also named “red sanders” or “red sandalwood”, is a rare, commercial tree in the Legume family. This species is distributed exclusively in well-defined forest tracts of Andhra Pradesh in Southern India. It is valuable in the international market and is most notably exported from India to Japan and other countries.¹ The fragrant red heartwood is valued for making furniture and also as a source of coloring and dyeing materials. In Buddhism, it represents holiness and is said to prevent evil; thus, it is used for carved statues and as a component of incense. In addition, *P. santalinus* has been used as a folk remedy for treatment of inflammation, such as in chronic bronchitis and chronic cystitis, fever, headaches, mental aberrations, ulcers, cancer, etc.^{2,3} In previous phytochemical investigations, six sesquiterpenes,⁴ one isoflavone,⁵ two lignans,² and two aurone glycosides⁶ were isolated from this species. In preliminary studies, we found that a MeOH extract of the heartwood exhibited potent cytotoxicity (IC₅₀ < 20 μg/mL) against six cancer cell lines (HepG2, Hep3B, Ca9-22, A549, MCF7, MDA-MB-231). Subsequently, we isolated seven benzofurans (1–7) and nine neoflavonoids (8–16) from the extract using bioactivity-guided fractionation. Compounds 1–5 and 8–13 are new, and their structures were determined by spectroscopic methods. Cytotoxic

and anti-inflammatory activities of the isolates were also investigated in this study.


RESULTS AND DISCUSSION

The CH₂Cl₂-soluble portion of a MeOH extract of *P. santalinus* heartwood was subjected to column chromatography (CC) on silica gel, C18 gel, Sephadex LH-20, and preparative TLC to yield five new benzofurans (1–5), six new neoflavonoids (8–13), and five known compounds (6, 7, 14–16). The known compounds were identified as dehydromelanoxin (6), melanoxin (7),⁷ melanoxin (14), *S*-3'-hydroxy-4,4'-dimethoxydalbergione (15), and melannein (16)⁸ by comparison of the NMR and MS data with those in published literature.

Compounds 1 and 6, isolated separately, both had the same molecular weight. The ion at *m/z* 300.0999 [M]⁺ in HREIMS indicated a molecular formula of C₁₇H₁₆O₅ and 10 degrees of unsaturation. Compounds 1 and 6 had similar ¹H and ¹³C NMR spectra. The IR spectra of 1 and 6 were also similar, with absorptions for OH (3443 cm⁻¹) and aromatic (1514 and

Received: November 30, 2010

Published: April 13, 2011



1512 cm^{-1} , respectively) groups. However, the UV spectra of **1** and **6** were significantly different. As indicated in the literature,⁹ 3-methyl- and 2-methyl-benzofurans show different λ_{max} absorptions, at ca. 321 and 235 nm, respectively. The UV spectrum of **1** showed a maximum absorption at 242 nm, whereas that of **6** showed a λ_{max} at 324 nm, which were consistent with the reported data. The methyl groups of **1** and **6** showed significantly different ^{13}C NMR chemical shifts (δ_{C} 13.6 in **1** and δ_{C} 9.6 in **6**).⁹ Therefore, the B rings in **1** and **6** are attached at C-3 and C-2, respectively, of the arylbenzofuran skeleton. On the basis of the ^1H and ^{13}C NMR spectra, compound **1** has a 14-carbon skeleton along with one methyl (δ_{H} 2.45/ δ_{C} 13.6) and two methoxy groups (δ_{H} 3.91/ δ_{C} 57.4, and δ_{H} 3.90/ δ_{C} 57.0). Five olefinic sp^2 methine carbons (δ_{C} 96.5, 105.2, 113.5, 116.9, and 121.4) and nine quaternary carbons [six oxygenated sp^2 carbons (δ_{C} 145.1, 147.3, 148.1, 148.4, 149.4, 150.9)] were observed according to HSQC and DEPT spectra. In the ^1H NMR spectrum, an ABX system (δ_{H} 6.99, $J = 2.0$ Hz; 7.07, $J = 8.0$ Hz; 6.94, $J = 8.0, 2.0$ Hz) and two singlet protons (δ_{H} 6.97 and 7.12) were found. The latter were identified on the basis of the HMQC spectra and a

previous reference⁹ as corresponding to C-4 (δ_{H} 6.97, δ_{C} 105.2) and C-7 (δ_{H} 7.12, δ_{C} 96.5). Moreover, these two aromatic protons showed HMBC correlations with C-5, C-6, C-9 and C-5, C-6, C-8, C-9, respectively. The HMBC spectrum also showed correlations of the OCH_3 protons at δ_{H} 3.91 and 3.90 with C-6 and C-4', which was confirmed by NOESY correlations with H-7 and H-5', respectively. Two OH protons (δ_{H} 7.30, 7.75) showed HMBC correlations with C-4, C-5, C-6 and C-2', C-3', which indicated that they were attached at C-5 and C-3'. Consequently, compound **1** has an isoparvifuran skeleton,⁹ and it was named pterolinus A.

The molecular formula ($\text{C}_{16}\text{H}_{14}\text{O}_4$) of **2** was identified from the HRESIMS ion at m/z 271.0972 [$\text{M} + \text{H}$]⁺, indicating 10 degrees of unsaturation. IR absorptions at 3317(OH) and 1510 (aromatic) cm^{-1} and UV absorptions at 321 and 284 nm were characteristic of a 2-methylbenzofuran.^{9,10} A 14-carbon skeleton was also proposed on the basis of the ^1H and ^{13}C NMR spectra. In contrast with **1**, the proton and carbon chemical shifts for the methyl group were observed at δ_{H} 2.36 s and δ_{C} 9.6. One OCH_3 group (δ_{H} 3.92), two OH groups (δ_{H} 7.23 br/8.60 br), and an AA'BB' (δ_{H} 6.96, d, $J = 8.0$ Hz/ δ_{H} 7.63, d, $J = 8.0$ Hz) system appeared in the ^1H NMR spectrum. The OCH_3 was connected to C-6 on the basis of a HMBC correlation and a NOE correlation with H-7. Hence, the two OH groups were assigned at C-5 and C-4'. Compound **2** was identified as indicated and has been named pterolinus B.

Compound **3** showed an [$\text{M} + \text{H}$]⁺ ion at m/z 317.1387 in the HRESIMS (molecular formula $\text{C}_{18}\text{H}_{20}\text{O}_5$), and nine degrees of unsaturation were calculated. The IR spectrum showed absorptions at 3408 (OH) and 1495, 1592 (aromatic) cm^{-1} , and UV maximum absorption were found at 207, 232, and 298 nm,⁷ indicating a 2,3-dihydrobenzofuran skeleton. On the basis of 1D NMR, one OH, one CH_3 , and three OCH_3 groups were found. Aromatic singlet protons, at δ_{H} 6.83 (H-4) and 6.51 (H-7), showed NOE correlations with δ_{H} 3.78 (OCH_3)/1.34 (CH_3) and δ_{H} 3.74 (OCH_3), respectively. The third OCH_3 was located at C-4' on the basis of an HMBC correlation with C-4' and an NOE correlation with H-5'. The OH group connected at C-3' according to the HMBC correlations with C-2' (δ_{C} 114.4) and C-3' (δ_{C} 148.2). The relative orientations of H-2 and H-3 in substituted 2,3-dihydrobenzofurans can be judged easily by ^1H NMR chemical shifts, with the *trans* form at ca. δ_{H} 5.11 and 3.38 vs the *cis* form at ca. δ_{H} 5.73 and 3.62.¹⁰ The chemical shifts of H-2 and H-3 in **3** were δ_{H} 5.02 and 3.29, which are consistent with a *trans* orientation. This assignment was confirmed by the absence of a NOE correlation. In addition, a negative Cotton effect at 319 nm and a positive Cotton effect at 255 nm in the CD spectrum, as well as a specific optical rotation value of -27.8 , were similar to those of a known compound ((2*S*,3*S*)-3-methyl-2-phenyl-2,3-dihydrobenz[*b*]furan, a negative Cotton effect at 280 nm and a positive Cotton effect at 220 nm, $[\alpha]_{\text{D}} -4.8$).¹⁰ The data suggested that the absolute configurations were 2*S* and 3*S*. Thus, compound **3** was identified as shown and was named pterolinus C.

Compound **4** showed an [$\text{M} + \text{Na}$]⁺ ion at m/z 357.0952 ($\text{C}_{17}\text{H}_{18}\text{O}_7\text{Na}$), corresponding to nine degrees of unsaturation. The IR spectrum showed OH, C=O, and aromatic absorptions, and a UV maximum absorption occurred at 230 nm. A 14-carbon skeleton was evident from 1D NMR, including seven methine carbons (four olefinic and three sp^3 carbons), seven quaternary carbons (three oxygenated carbons, an oxygenated sp^3 carbon, and two carbonyl carbons), a methyl, and two OCH_3 groups. In

Table 1. ^1H NMR Data of Compounds 1–7 (400 MHz in acetone- d_6 , J values in parentheses)

	1	2 ^a	3	4	5	6	7
1				4.28 d (4.0)	4.25 d (4.0)		
2			5.02 d (8.0)	4.77 dd (10.0, 4.0)	4.68 d (7.6, 4.0)		4.98 d (8.2)
3			3.29 m (8.0, 6.8, 0.8)	1.81 dq (10.0, 7.2)	3.28 p (7.6)		3.27 p (8.2, 6.8)
4	6.97 s	6.96 s	6.83 d (0.8)			6.96 s	6.66 d (1.2)
5				3.93 s	6.62 s		
6							
7	7.12 s	7.13 s	6.51 s			7.13 s	6.49
8				5.91 s	5.99 s		
9							
1'							
2'	6.99 d (2.0)	7.63 d (8.0)	6.91 d (2.0)	6.88 d (2.0)	6.87 d (2.0)	7.28 d (2.4)	6.91 d (8.0)
3'		6.96 d (8.0)					
4'							
5'	7.07 d (8.0)	6.96 d (8.0)	6.93 d (8.0)	6.89 d (8.0)	6.86 d (8.0)	7.04 d (8.4)	6.49 d (8.0)
6'	6.94 dd (8.0, 2.0)	7.63 d (8.0)	6.86 dd (8.0, 2.0)	6.80 dd (8.0, 2.0)	6.76 d (8.0, 2.0)	7.21 dd (8.4, 2.4)	6.86 dd (8.0, 2.0)
5-OCH ₃			3.78 s				
6-OCH ₃	3.91 s	3.92 s	3.74 s			3.91 s	3.84 s
7-OCH ₃				3.83 s	3.82 s		
4'-OCH ₃	3.90 s		3.84 s	3.83 s	3.83 s	3.89 s	3.81 s
5-OH	7.30 s	7.23 br				7.34 s	6.95 s
3'-OH	7.75 s		7.73 s	7.54 s	7.50 s	7.86 s	7.65 s
4'-OH		8.60 br					
CH ₃	2.45 s	2.36 s	1.34 d (6.8)	1.04 d (7.2)	0.97 d (7.6)	2.37 s	1.32 d (6.8)

^a Recorded by 500 MHz NMR.

the ^1H NMR spectrum, an ABX system (δ_{H} 6.88, $J = 2.0$ Hz; 6.89 $J = 8.0$ Hz; 6.80 $J = 8.0, 2.0$ Hz) was found, together with an olefinic methine, an oxymethine, and two OH groups. A $\text{CH}_3\text{—CH—CH—OH}$ fragment (1.04, $J = 7.2$ Hz, $\text{CH}_3/1.81$, $J = 10.0, 7.2$ Hz, H-3/4.77, $J = 10.0, 4.0$ Hz, H-2/4.28, $J = 4.0$ Hz, OH) was present. Proton signals at δ_{H} 6.88 and 6.80 showed a HMBC correlation with C-2 (δ_{C} 76.3), indicating that ring B was attached at C-2. Two unique carbons (δ_{C} 62.5, 65.1) of ring A were observed in the ^{13}C NMR spectrum, and a singlet proton at δ_{H} 3.93 showed HMBC correlations with δ_{C} 47.1, 65.1, 160.3, and 189.5. On the basis of this data, there was a C4—C-5 epoxide. The olefinic proton (δ_{H} 5.91, s) showed correlations with δ_{C} 65.1, 160.3, 189.5, and 193.5, providing evidence that ring A also contained two carbonyl groups. The OCH_3 groups in 4 showed HMBC correlations with C-7 and C-4' and NOESY enhancements with H-8 and H-5', which indicated that the OCH_3 substituents were located at C-6 and C-4'. The coupling constant ($J = 7.6$ Hz) of H-2 and H-3 in compound 4 indicated that the dihedral angle ϕ of these vicinal protons was near 0° or 150° . However, a weak NOE correlation was observed between H-2 and H-3, which suggested that both dihedral angles (0° or 150°) were possible. Therefore, we were not able to determine the structure of 4 by means of NMR techniques. We attempted to determine the absolute configuration in 4 by a Mosher's reaction, but were unable to distinguish the positive side and negative side after calculating $\delta_{\text{S-MTPA}} - \delta_{\text{R-MTPA}}$. Thus, the structure of 4 was identified as shown, and it was named pterolinus D.

Compound 5 had the molecular formula $\text{C}_{17}\text{H}_{18}\text{O}_6$, one oxygen atom less than 4. The IR spectrum showed absorptions indicative of OH, C=O , and aromatic groups, and the UV had maximum absorption at 230 and 273 nm. The epoxide carbons of

4 were absent and instead were replaced by carbons resonating at δ_{C} 153.7 and 132.2. Thus, a 1,4-benzoquinone was present. H-2 and H-3 of compound 5 showed a large coupling constant ($J = 10$ Hz) and no NOE correlation, indicating that these two protons had an *anti* conformation. Because NOE correlations were found between H-2 and the two vicinal groups, C3-Me and H-5, any of four isomers were possible. Therefore, the stereochemistry was not defined. Compound 5 was named pterolinus E.

Compound 8 had a molecular formula of $\text{C}_{18}\text{H}_{18}\text{O}_6$, with nine degrees of unsaturation. On the basis of comparison with previously reported ^{13}C NMR data,¹¹ a neoflavonoid skeleton was identified in 8. The ^1H NMR spectrum exhibited an ABX system (δ_{H} 6.66, $J = 8.4, 2.4$ Hz/6.86, $J = 8.4$ Hz/6.71, $J = 2.4$ Hz), two aromatic singlet signals (δ_{H} 6.73/7.30), three OH groups (δ_{H} 7.48, br/8.16, br/10.16, s), and two OCH_3 groups (δ_{H} 3.80, s/3.91, s). ^1H NMR, COSY, and HSQC data established the partial connectivity of the C7—C8—C9 segment and identified the carbons as an aliphatic CH, an olefinic CH, and an olefinic CH_2 . Two singlet aromatic protons in the ^1H NMR spectrum revealed the presence of a 1,2,4,5-tetrasubstituted phenyl ring A. In the HMBC spectrum, both H-6 and H-6' showed correlations with C-7, suggesting that the two phenyl groups were connected through C-7. In addition, one OCH_3 group (δ_{H} 3.91) showed an HMBC correlation with the carbonyl carbon at δ_{C} 171.7, which indicated the presence of a methyl ester. The OH proton at δ_{H} 10.16 showed HMBC correlations with C-4 (δ_{C} 111.5) and C-6 (δ_{C} 119.2), while H-3 showed correlations with C-1, C-2, CO, and C-5. These data indicated that ring A was *para*-hydroxy substituted. Furthermore, on the basis of the HMBC and NOESY spectra, the OCH_3 group (δ_{H} 3.80) was assigned at C-4'. The absolute configuration was

Table 2. ¹H NMR Data of Compounds 8–15 (400 MHz in acetone-*d*₆, *J* values in parentheses)

	8	9	10 ^a	11 ^d	12 ^b	13	14 ³	15	16 ^c
1									
2		6.50 s				6.24 d (1.2)	6.86 s		7.49 s
3	7.30 s		5.42 s	5.42 s	5.11 s			6.00 s	
4									
5		6.57 s				6.38 s	7.69 s		7.07 s
6	6.73 s		6.47 s	6.48 s	2.36 d (11.4) 2.71 dd (11.4, 1.2)			6.45 d (1.2)	
7	5.05 brd (7.2)	4.74 brd (7.2)	4.68 d (6.5)	4.64 d (7.0)	3.50 brd (7.5)	3.98 brd (6.8)		4.79 dd (1.2, 7.2)	
8	6.31 ddd (17.0, 10.0, 7.2)	6.26 ddd (17.0, 10.2, 7.0)	6.10 ddd (17.0, 10.0, 6.5)	6.09 ddd (17.0, 10.0, 7.0)	6.07 ddd (17.4, 10.5, 7.5)	2.01 m 2.17 m		6.19 ddd (17.2, 10.4, 7.2)	6.44
9	4.97 dt (17.0, 1.6)	4.90 dt (17.0, 1.6)	4.92 d (17.0)	4.91 dt (10.0, 1.5)	4.85 ddd (17.4, 2.4, 1.8)	4.09 m		5.02 dt (17.2, 1.6)	
	5.18 dt (10.0, 1.6)	5.11 ddd (10.2, 2.4, 1.6)	5.10 d (OL) ^d	5.09 dt (1.5, 17.0)	5.05 ddd (10.5, 1.8, 1.2)			5.20 dt (10.4, 1.6)	
1'									
2'	6.71 d (2.4)	6.69 d (2.4)	6.67 d (2.0)	6.71 d (2.0)	6.52 d (0.6)	6.78 d (2.0)	7.77 d (2.0)	6.73 d (2.4)	7.01 ^e
3'									
4'									
5'	6.86 d (8.4)	6.83 d (8.4)	6.83 d (8.4)	6.82 d (8.0)	7.23 s	6.75 d (8.0)	6.92 d (8.4)	6.87 d (8.4)	7.01 ^e
6'	6.66 dd (8.4, 2.4)	6.64 dd (8.4, 2.4)	6.63 dd (8.4, 2.0)	6.64 dd (8.0, 2.0)	3.22 s	6.57 dd (8.0, 2.0)	7.38 d (8.4, 2.0)	6.67 dd (8.4, 2.4)	7.41 brdd
1-OCH ₃					3.72 s				
2-OCH ₃									
4-OCH ₃									
5-OCH ₃									
3'-OCH ₃									
4'-OCH ₃	3.80 s	3.79 s	3.79 s	3.79 s	3.81 s				
2-OH	8.16 br	7.57 br				3.79 s	3.80 s	3.83 s	3.84 s
3-OH						3.78			
5-OH	10.16 s	7.40 br	5.10 s	5.08 s	5.21 s				
3'-OH	7.48 br	6.88 br	7.44 s	7.39 s	7.59 s				
4'-OH						7.42 s			
COOCH ₃	3.91 s								
CH ₂			2.95 d (14.5)	2.93 d (14.5)					
			3.06 d (14.5)	3.04 d (14.5)					
			2.14 s	2.10 s					
COCH ₃									

^a Recorded by 500 MHz NMR in acetone-*d*₆. ^b Recorded by 600 MHz NMR in acetone-*d*₆. ^c Measured in pyridine-*d*₅. ^d Overlapping with 5-OH. ^e Overlapping.

identified as **7S** by comparing the $[\alpha]_D$ value (+20.6) with previous references (latifolin, **7R**, $[\alpha]_D^{20}$ -26.7; 2,4-dihydroxydalbergiquinol, **7S**, $[\alpha]_D^{22}$ +34.7).^{11,12} Thus, the structure of **8** was elucidated, and the compound was named pterolinus F.

Compound **9** was obtained as a 2:5 mixture with **15**, according to ^1H NMR data, even when different purification methods were used. Compound **15** was isolated as a pure compound that contains a 1,4-benzoquinone ring, as elucidated in an earlier report,^{11,13} while **9** contains 1,4-hydroxy-substituted phenyl rings (see OH signals in Table 2). To further suggest that **15** was the oxidative product of **9**, the latter compound showed an $[\text{M}]^+$ ion at m/z 302.1151 ($\text{C}_{17}\text{H}_{16}\text{O}_5$) in the HRGCEIMS, while the former compound showed an $[\text{M} + \text{H}]^+$ ion at m/z 300.97 ($\text{C}_{17}\text{H}_{17}\text{O}_5$) in the ESIMS, 2 amu less than **9**. In addition, excess NaBH_4 was used to reduce compound **15** to confirm that **9** was the hydroquinone counterpart of **15** (data are shown in Supporting Information). We postulate that **9** is oxidized gradually to **15** and that both compounds should have an *S* configuration at C-7. Compound **9** was named pterolinus G.

Compounds **10** and **11** were isolated by RI-recycle HPLC (EtOAc-hexanes, 2:1, t_R = 32.4 and 35.6 min). Both compounds had the molecular weight $\text{C}_{20}\text{H}_{23}\text{O}_6$. On the basis of similar NMR data, **10** and **11** both had a neoflavonoid C7-C8-C9 fragment and a 3-hydroxy-4-methoxyphenyl ring. However, unlike **15**, compounds **10** and **11** had a $-\text{CH}_2-\text{CO}-\text{CH}_3$ moiety (δ_{H} 2.95, 3.06, J = 14.5 Hz, δ_{C} 52.3/ δ_{C} 205.6/ δ_{H} 2.14, s, δ_{C} 31.9) and an OH (δ_{H} 5.10, s) rather than a second carbonyl group in ring A, based on 1D NMR and HMBC data. In the HMBC data of **10**, H-7 (δ_{H} 4.68) showed correlations with C-1 (δ_{C} 139.4) and C-2 (δ_{C} 185.8), and the proton of an OH group showed correlations with C-4, C-5, C-6, and $-\text{CH}_2-\text{CO}-\text{CH}_3$. Therefore, the $-\text{CH}_2-\text{CO}-\text{CH}_3$ and OH substituents were both attached to the C-5 of ring A. On the other hand, the HMBC spectrum of **11** also showed correlation patterns similar to those of **10**. Both **10** and **11** showed positive $[\alpha]_D^{25}$ values ($[\alpha]_D^{25}$ 142.12/105.96) and a negative Cotton effect at ca. 340 nm and positive Cotton effect at ca. 300 nm. By comparisons with previous data (shown in Supporting Information),¹³ we suggest that C-7 has an *S* configuration. However, we could not identify the absolute configuration at C-5. Thus, **10** and **11** were identified as epimers and were named pterolinus Ha and pterolinus Hb. However, these two epi-isomers could possibly be artifacts due to reaction with acetone.

The molecular formula of **12** was $\text{C}_{18}\text{H}_{20}\text{O}_6$, with nine degrees of unsaturation. On the basis of the ^{13}C NMR data, a 15-carbon skeleton and three OCH_3 groups were found. The ^1H NMR and COSY data revealed a $-\text{C}7-\text{C}8-\text{C}9$ moiety; however, the H-7 signal was shifted to δ_{H} 3.50 (d, J = 7.5 Hz), indicating that one aromatic ring was absent. Two quaternary, one methylene, and one carbonyl carbon were found in the 1D NMR spectra. From the HMBC data, H-7 showed key correlations with C-1, C-6, C-1', and C-6', revealing that this partial structure was linked to C-7. In addition, H-6a and H-6b showed HMBC correlation with C-1, C-2, C-4, C-5, and C-1', and H-6b showed a long-range coupling (J = 1.2 Hz) with H-8 (δ_{H} 5.05). Moreover, H-5' showed HMBC correlations with C-5, C-4', and C-6'. Thus, compound **12** was tricyclic and linked between C-5 and C-6'. The relative configuration was assigned from the NOESY spectrum, in which H₂-6 showed no correlation with H-7, suggesting that these two protons are on a different side than H-7. The absolute configuration could not be identified in the current study. The three OCH_3 groups (δ_{H} 3.22, 3.72, 3.81)

showed NOE correlations with H-6b, H-3, and H-5', respectively, and the structure was assigned as shown. Compound **12** was named pterolinus I.

Compound **13** had the molecular formula $\text{C}_{17}\text{H}_{19}\text{O}_5$, corresponding to nine degrees of unsaturation. The ^1H NMR and HMQC spectra demonstrated that the terminal double bond (C-8, C-9) found in **8**–**12** was absent and instead was replaced by substituted methylene (δ_{H} 2.01, 2.17, m, δ_{C} 33.6) and oxygenated methylene (δ_{H} 4.09, m, δ_{C} 65.4) groups. On the basis of nine degrees of unsaturation, the presence of a heterocyclic ring C was postulated. HMBC correlations of H-5 (δ_{H} 6.38, s) with C-4 (δ_{C} 148.5) and C-6 (δ_{C} 149.7), as well as correlations of H-9 with C-6 and C-7 (δ_{C} 41.7), indicated that C-9 was linked to C-6 through an oxygen atom. The positions of the two OCH_3 and two OH groups at C-4, C-3', C-3, and C-4', respectively, were confirmed from the NOESY and HMBC data. Thus, **13** was identified and was named pterolinus J.

Compounds **1**–**8**, **10**, **11**, and **13**–**16** were screened for cytotoxicity against six human cancer cell lines, liver (HepG2, Hep3B), gingival (Ca9-22), lung (A549), and breast (MCF7, MDA-MB-231), and for anti-inflammatory activity based on effects against superoxide anion generation and elastase release by human neutrophils in response to fMLP/CB.

These compounds could be divided into those with a benzofuran skeleton and those with a neoflavonoid skeleton. Among the neoflavonoids (**8**, **10**, **11**, **13**–**16**), compound **14** showed the highest cytotoxicity against Ca9-22, with an IC_{50} value of 0.46 $\mu\text{g}/\text{mL}$, **15** showed significant cytotoxicity against Hep3B and MDA-MB-231 with IC_{50} values of 2.39 and 3.34 $\mu\text{g}/\text{mL}$, **10** exhibited cytotoxicity against HepG2 and MDA-MB-231 with IC_{50} values of 3.65 and 2.85 $\mu\text{g}/\text{mL}$, and compound **11** showed selective cytotoxicity against A549 with an IC_{50} value of 3.97 $\mu\text{g}/\text{mL}$. In contrast, compounds **13** and **16**, which contain a pyran or lactone ring C formed by cyclization of a $-\text{C}7-\text{C}8-\text{C}9-\text{O}-$ moiety onto ring B, were inactive ($\text{IC}_{50} > 17.10$ $\mu\text{g}/\text{mL}$). Therefore, the heterocyclic ring C abolished cytotoxic activity. Compounds **8**, **10**, **11**, **14**, and **15** have identical phenyl B rings, but differences in the A rings and linkage between the two rings. Compound **8**, with a *para*-dihydroxy-substituted phenyl ring A, exhibited only weak cytotoxicity (IC_{50} 11.10–16.10 $\mu\text{g}/\text{mL}$) compared with **10**, **11**, and **15**, which contain benzoquinone or similar ring systems containing carbonyl groups. Compound **14**, which has a carbonyl (C=O) linkage between the phenyl A and B rings rather than an allyl ($\text{CH}-\text{CH}=\text{CH}_2$) group, exhibited potent cytotoxicity against Ca9-22. Therefore, compound **14** could be a potential candidate for anticancer drug development.

Among the benzofurans (**1**–**7**), compound **2** showed the highest cytotoxicity against A549 and MCF7, with IC_{50} values of 2.34 and 1.74 $\mu\text{g}/\text{mL}$, while compound **6**, with a different substitution pattern on ring B, and compound **1**, with ring B attached at C-2 rather than C-3, exhibited no cytotoxicity. Compounds **3** and **7**, with a *trans*-configured saturated C2–C3 bond, were inactive (>19.42 $\mu\text{g}/\text{mL}$) or weakly active (7.70–15.42 $\mu\text{g}/\text{mL}$). Compound **4**, with an opened ring C and benzoquinone ring A, showed significant cytotoxicity against Hep3B and MCF7 (IC_{50} 2.08 and 3.31 $\mu\text{g}/\text{mL}$) and moderate cytotoxicity against HepG2 and MDA-MB-241 (IC_{50} 4.33 and 4.89 $\mu\text{g}/\text{mL}$). Compound **5**, which is structurally identical to **4**, except for lacking the epoxide group, exhibited reduced activity (IC_{50} 6.96–16.65 $\mu\text{g}/\text{mL}$).

Compounds **1**–**8**, **10**, **11**, and **13**–**16** were evaluated for inhibitory effects on superoxide anion generation and elastase

release by human neutrophils in response to fMLP/CB. The benzofurans generally showed more potent inhibition than neoflavonoids (Table 5). Compounds **1**, **2**, **4**, **6**, and **7** showed potent inhibition of superoxide anion generation with IC₅₀ values of 0.33, 0.19, 0.29, 0.73, and 0.69 μg/mL, respectively. The inhibition was 1.6–6.2-fold greater than that of the positive control LY294002 (a phosphatidylinositol-3-kinase inhibitor).^{14,15} In addition, compound **4** showed significant inhibition of human neutrophil elastase release with an IC₅₀ value of 1.06 μg/mL, which was 1.9-fold higher than the positive control. Among the neoflavonoids, compound **15** exhibited potent inhibition in both assays with IC₅₀ values of 0.47 and 1.44 μg/mL (Table 5). On the basis of the results, compounds **1**, **2**, **4**, **6**, **7**, and **15** merit consideration as leads for anti-inflammatory agents.

EXPERIMENTAL SECTION

General Experimental Procedures. CD data were measured on a JASCO J-815 instrument. Optical rotations were recorded on a JASCO P-1020 polarimeter. IR spectra were measured on a Mattson Genesis II FT-IR spectrophotometer. UV spectra were obtained on a JASCO V-530 UV/vis spectrophotometer. NMR spectra were run on a Varian Unity-plus 400 MHz FT-NMR or a Varian Mercury-plus 400 MHz FT-NMR spectrometer. The chemical shift (δ) values are in ppm (parts per million) with *d*₆-acetone, *d*₄-MeOH, or *d*₅-pyridine as the internal standard, and coupling constants (*J*) are in Hz. Low-resolution ESI-mass spectra were obtained on a VG Biotech Quattro 5022 mass spectrometer in a positive or negative mode, high-resolution MS spectra were obtained on Bruker Daltonics APEX α30e and JEOL JMS-700 mass spectrometers. A JASCO PU986 pump, a JASCO UV-1575 detector, a JASCO 887-30 mix. Module, a JAILC-918 RI-recycle HPLC, and an Ascentis C18 column (250 mm × 10 mm, 5 μm) were employed for HPLC separations. The Biotage SP1 was used for flash liquid chromatography. Silica gel 60 (40–60 mesh, Merck), C-18 (40–63 mesh, Merck), Sephadex LH-20, Celite 545, and Diaion HP-20 were used for column chromatography. Silica gel plates (Kieselgel 60, F254, 0.20 nm, Merck) were used for TLC.

Plant Material. Heartwood (4.75 kg) of *P. santalinus* was imported from India, provided by Mr. Mike Y. C. Wei, and was identified by Prof. Dr. Sheng-Yang Wang, Department of Forestry, National Chung-Hsing University, Taichung, Taiwan. A voucher specimen (Pterocarpus 002) was deposited in the Graduate Institute of Natural Products, Kaohsiung, Taiwan.

Extraction and Isolation. The heartwood was powdered and extracted with MeOH (5 × 20 L). After removal of solvent, the crude extract (ca. 480 g) was partitioned between CH₂Cl₂ and 50% aqueous MeOH. The CH₂Cl₂ layer was concentrated in vacuo, and the CH₂Cl₂ extract (ca. 300 g) was subjected to CC on Celite 545 and eluted with *n*-hexane (8 L), CH₂Cl₂ (40 L), EtOAc (20 L), acetone (10 L), and MeOH (8 L). Six fractions (PS-C1 to PS-C6) were obtained. PS-C3 (ca. 100 g) was subjected to silica gel CC using a hexane–EtOAc–MeOH gradient solvent system (3:1:0, 1:1:0, 0:1:0, 0:40:1, 0:20:1, 0:10:1, 0:6:1), to give 11 fractions (PS-C3.1 to PS-C3.11).

Compounds **14** (3.6 g) and **16** (ca. 8 g) were obtained as precipitated solids from PS-C3.6 and PS-C3.7, and **6** (144 mg) was obtained from PS-C3.5. PS-C3.5 (31.2 g) was subjected to repeated silica gel CC with a CH₂Cl₂ and MeOH gradient solvent system, and 11 fractions (PS-C3.5.1 to PS-C3.5.11) were obtained. PS-C3.5.6 (20.70 g) was subjected to CC on Sephadex LH-20 and eluted with acetone and CH₂Cl₂ (1:1) to give 10 fractions (PS-C3.5.6.1 to PS-C3.5.6.10). PS-C3.5.6.3 (6.0 g) was repeatedly chromatographed on RP-MPLC, Sephadex LH-20, NP-RI-HPLC, silica gel, and PTLC to give **3** (9.8 mg), **10** (25 mg), **11** (15.1 mg), **12** (0.6 mg), and **15** (42 mg). PS-C3.5.6.5 and PS-C3.5.6.6 were mixed (total ca. 6.8 g) and subjected to CC with Sephadex LH-20, RP-MPLC, silica gel, and PTLC to give **4** (16.5 mg), **5** (12 mg), and **7** (1.6 g).

Table 3. ¹³C NMR Data (δ) of Compounds **1**–**7** (100 MHz in acetone-*d*₆)

	1	2 ^a	3	4	5	6	7
1							
2	150.9	151.1	94.0	76.3	78.1	151.3	93.8
3	117.8	110.0	47.2	47.1	41.2	125.4	47.1
4	105.2	104.2	111.0	65.1	153.7	104.9	111.6
5	145.1	148.5	151.8	62.5	132.2	147.9 ^b	142.2
6	147.3	147.1	145.6	189.5	183.5	149.1	148.7 ^b
7	96.5	95.7	96.8	160.3	160.0	96.3	96.1
8	149.4	144.4	155.1	110.5	109.2	145.0	153.8
9	122.8	124.8	123.6	193.5	188.4	111.2	124.3
1'	127.5	124.3	135.9	138.5	138.4	125.4	135.9
2'	116.9	128.6	114.4	115.0	115.0	114.4	114.4
3'	148.4	116.5	148.2	148.1	147.8 ^b	148.2 ^b	148.2 ^b
4'	148.1	158.0	149.0	148.6	148.3 ^b	148.7 ^b	148.9 ^b
5'	113.5	116.5	112.9	112.5	112.4	113.3	112.9
6'	121.4	128.6	118.9	119.8	119.5	119.4	118.9
5-OCH ₃			57.0				
6-OCH ₃	57.4	56.8	58.1			56.9	56.9
7-OCH ₃				57.7 ^b	57.2 ^b		
4'-OCH ₃	57.0		56.9	56.9 ^b	56.9 ^b	57.4	57.2
CH ₃	13.6	9.6	19.4	14.7	17.8	10.3	19.3

^a Recorded by 125 MHz NMR. ^b The chemical shifts may be interchanged.

PS-C3.5.6.7 (478 mg) was separated by RP-MPLC with a MeOH and H₂O gradient system and divided into five subfractions, while compound **13** (7.6 mg) was isolated by RP-HPLC (Ascentis, 250 × 10 mm, 57% MeOH(aq)) from subfraction 3. PS-C3.5.6.8 (0.27 g) was separated by RP-MPLC with 60% MeOH(aq), and eight subfractions were obtained, while compounds **1** and **8** were isolated by PTLC with pure CH₂Cl₂ from subfraction 7 (70.7 mg). PS-C3.5.6.9 (533 mg) was separated by RP-MPLC with a MeOH and H₂O gradient to give nine fractions, while **2** (19.2 mg) and **9** (9.7 mg) were isolated by PTLC with pure CH₂Cl₂ from subfraction 3 (117.6 mg).

Pterolinus A (**1**): brown gum; UV λ^{MeOH}_{max} nm (log ε) 242 (4.13), 297 (3.97), 309 (3.84), 350 (3.33); IR (neat) ν_{max} 3443, 2930, 1621, 1514 cm⁻¹; ¹³C and ¹H NMR data, see Table 1; HREIMS *m/z* 300.0999 [M]⁺ (calcd 300.0999 for C₁₇H₁₆O₅).

Pterolinus B (**2**): amorphous, pale brown powder; UV λ^{MeOH}_{max} nm (log ε) 226 (4.00), 284 (4.05), 321 (4.28), 337 (4.08); IR (neat) ν_{max} 3317, 2921, 1677, 1510 cm⁻¹; ¹³C and ¹H NMR data, see Table 2; ESIMS *m/z* 270.99 [M + H]⁺; HRESIMS *m/z* 271.0972 [M + H]⁺ (calcd 271.0970 for C₁₆H₁₅O₄).

Pterolinus C (**3**): amorphous, pale brown powder; [α]_D²⁵ -27.8 (c 0.095, MeOH); UV λ^{MeOH}_{max} nm (log ε) 207 (4.44), 232 (3.93), 289 (3.72), 298 (3.69); CD ε₃₁₅ -11.08, Δε₂₅₈ 29.26 (MeOH; c = 0.3 mg/mL); IR (neat) ν_{max} 3408, 2928, 1592, 1495 cm⁻¹; ¹³C and ¹H NMR data, see Table 3; ESIMS *m/z* 316.93 [M + H]⁺; HRESIMS *m/z* 317.1387 [M + H]⁺ (calcd 317.1389 for C₁₈H₂₁O₅).

Pterolinus D (**4**): amorphous, brown powder; [α]_D²⁵ -116.0 (c 0.10, MeOH); UV λ^{MeOH}_{max} nm (log ε) 230 (4.04), 264 (3.86), 278 (3.86); CD Δε₃₂₉ -93.23, Δε₂₉₃ +26.64 (MeOH; c = 0.3 mg/mL); IR (neat) ν_{max} 3433, 2922, 1715, 1667, 1609, 1511 cm⁻¹; ¹³C and ¹H NMR data, see Table 3; ESIMS *m/z* 357 [M + Na]⁺; HRESIMS *m/z* 357.0952 [M + Na]⁺ (calcd 357.0950 for C₁₇H₁₈O₇Na).

Pterolinus E (**5**): amorphous, brown powder; [α]_D²⁵ -10.4 (c 0.10, MeOH); UV λ^{MeOH}_{max} nm (log ε) 230 (4.16), 273 (4.04), 313 (3.82); CD Δε₃₈₄ +9.67, Δε₃₁₃ -7.51 (MeOH; c = 0.3 mg/mL); IR (neat) ν_{max}

Table 4. ^{13}C NMR Data (δ) of Compounds 8–15 (100 MHz in acetone- d_6)

	8	9	10 ^a	11 ^a	12 ^b	13	14 ^c	15	16 ^b
1	148.5	123.3	139.4	139.5	82.2	118.2	112.6	152.0	112.4
2	142.0	148.7	185.8	185.9	185.0	117.2	159.8	187.6	112.2
3	115.6	102.1	101.8	101.8	101.3	141.7	101.1	109.1	114.9
4	111.5	147.6 ^d	174.8	174.8	198.9	148.5	156.3	160.3	152.5
5	156.5	141.0	69.9	69.9	74.1	101.8	140.3	187.3	100.6
6	119.2	117.1	143.4	143.3	40.2	149.7	118.7	132.5	155.8
7	48.9	47.9	46.8	47.2	51.8	41.7	199.3	48.0	149.7
8	141.5	142.8	140.9	140.9	141.4	33.6		139.8	111.8
9	117.0	115.9	116.2	116.2	117.3	65.4		118.2	161.6
1'	136.7	138.2	135.3	135.5	133.7	139.0	132.1	134.3	129.2
2'	117.0	117.0	116.4	116.5	118.5	113.4	117.3	116.9	120.0
3'	147.6	147.6 ^d	146.9	147.2	147.9	149.0	148.0	148.0 ^d	148.3
4'	148.0	147.3 ^d	147.2	146.9	148.0	146.7	151.8	148.2 ^d	149.4
5'	113.0	112.8	112.2	112.2	109.1	116.2	111.1	113.1	112.2
6'	120.9	120.8	120.5	120.3	128.1	122.6	122.0	121.0	116.7
1-OCH ₃					52.0				
2-OCH ₃					57.9				
4-OCH ₃		56.9	56.3	56.4		56.8		57.3	55.9
5-OCH ₃							56.0		
3'-OCH ₃						56.9			
4'-OCH ₃	56.9	57.0	56.4	56.3	56.9		55.8	56.9	56.1
COOCH ₃	53.4								
COOCH ₃	171.7								
CH ₂			52.3	52.1					
COCH ₃			31.9	31.9					
COCH ₃			205.6	205.7					

^a Recorded by 125 MHz NMR in acetone- d_6 . ^b Recorded by 150 MHz NMR in acetone- d_6 . ^c Measured in pyridine- d_5 . ^d The chemical shifts are interchangeable.

3419, 2924, 1681, 1606, 1509 cm^{-1} ; ^{13}C and ^1H NMR data, see Table 3; ESIMS m/z 341 $[\text{M} + \text{Na}]^+$; HRESIMS m/z 341.0998 $[\text{M} + \text{Na}]^+$ (calcd 341.1001 for $\text{C}_{17}\text{H}_{18}\text{O}_6\text{Na}$).

Pterolinus F (**8**): yellow, colorless oil; $[\alpha]_D^{25} +20.6$ (c 0.11, CH_2Cl_2); UV $\lambda_{\text{max}}^{\text{MeOH}}$ nm ($\log \epsilon$) 220 (4.23), 253 (3.88), 285 (3.62), 341 (3.68); CD $\Delta\epsilon_{363} -4.15$, $\Delta\epsilon_{307} -12.12$, $\Delta\epsilon_{266} +2.51$ (EtOH; c = 0.3 mg/mL); $\epsilon_{329} -2.57$, $\Delta\epsilon_{266} +2.13$, $\Delta\epsilon_{255} -2.12$ (MeOH; c = 0.5 mg/mL); IR (neat) ν_{max} 3419, 2955, 1677, 1623, 1510 cm^{-1} ; ^{13}C and ^1H NMR data, see Table 3; ESIMS m/z 331.10 $[\text{M} + \text{H}]^+$; HRESIMS m/z 331.1185 $[\text{M} + \text{H}]^+$ (calcd 331.1182 for $\text{C}_{18}\text{H}_{19}\text{O}_6$).

Pterolinus G (**9**): brown gum; UV $\lambda_{\text{max}}^{\text{MeOH}}$ nm ($\log \epsilon$) 261 (3.92); IR (neat) ν_{max} 3420, 2928, 1670, 1600, 1514 cm^{-1} ; ^{13}C and ^1H NMR data, see Table 3; HREIMS m/z 300.1000 $[\text{M}]^+$ (calcd 300.0998 for $\text{C}_{17}\text{H}_{16}\text{O}_5$), 302.1151 $[\text{M}]^+$ (calcd 302.1151 for $\text{C}_{17}\text{H}_{18}\text{O}_5$).

Pterolinus Ha (**10**): brown gum; $[\alpha]_D^{25} +142.12$ (c 0.12, CH_2Cl_2); UV $\lambda_{\text{max}}^{\text{MeOH}}$ nm ($\log \epsilon$) 232 (4.43), 280 (4.12), 399 (3.37); CD $\epsilon_{343} -23.87$, $\Delta\epsilon_{325} -19.51$, $\Delta\epsilon_{295} +4.33$ (EtOH; c = 0.3 mg/mL); IR (neat) ν_{max} 3392, 2922, 1704, 1664, 1609, 1507 cm^{-1} ; ^{13}C and ^1H NMR data, see Table 3; ESIMS m/z 359.14 $[\text{M} + \text{H}]^+$; HRESIMS m/z 359.1494 $[\text{M} + \text{H}]^+$ (calcd 359.1495 for $\text{C}_{20}\text{H}_{23}\text{O}_6$).

Pterolinus Hb (**11**): brown gum; $[\alpha]_D^{25} +106.0$ (c 0.094, CH_2Cl_2); UV $\lambda_{\text{max}}^{\text{MeOH}}$ nm ($\log \epsilon$) 232 (4.66), 282 (4.36), 399 (3.50); CD $\epsilon_{349} -20.13$, $\epsilon_{305} +24.37$ (EtOH; c = 0.3 mg/mL); IR (neat) ν_{max} 3418, 2922, 1705, 1606, 1510 cm^{-1} ; ^{13}C and ^1H NMR data, see Table 3; ESIMS m/z 359.14 $[\text{M} + \text{H}]^+$; HRESIMS m/z 359.1494 $[\text{M} + \text{H}]^+$ (calcd 359.1495 for $\text{C}_{20}\text{H}_{23}\text{O}_6$).

Table 5. Inhibitory Effects of Compounds 1–8, 10, 11, and 13–16 on Superoxide Anion Generation and Elastase Release by Human Neutrophils in Response to FMLP/CB

compound	superoxide anion	elastase release
	IC_{50}^a ($\mu\text{g}/\text{mL}$) or (Inh %) ^b	IC_{50} ($\mu\text{g}/\text{mL}$) or (Inh %)
1	0.33 ± 0.38	2.54 ± 0.57
2	0.19 ± 0.03	(47.83 ± 4.63) ^f
3	2.28 ± 0.79	(9.73 ± 2.95) ^d
4	0.29 ± 0.07	1.06 ± 0.24
5	NT	2.13 ± 0.19
6	0.73 ± 0.20	3.69 ± 0.19
7	0.69 ± 0.19	(33.33 ± 7.33) ^e
8	NT	3.22 ± 1.01
10	(29.44 ± 7.71) ^d	(19.53 ± 7.60)
11	(34.15 ± 7.76) ^d	(2.84 ± 5.74)
13	2.10 ± 0.29	(16.59 ± 6.99)
14	NT	3.62 ± 0.71
15	0.47 ± 0.04	1.44 ± 0.11
16	3.18 ± 0.48	(−1.53 ± 2.90)
LY294002 ^c	1.18 ± 0.24	1.99 ± 0.35

^a Concentration necessary for 50% inhibition (IC_{50}). ^b Percentage of inhibition (Inh %) at 10 $\mu\text{g}/\text{mL}$ concentration. Results are presented as mean ± SEM (n = 3–5). ^c LY294002, a phosphatidylinositol-3-kinase inhibitor, was used as a positive control for superoxide anion generation and elastase release. ^d p < 0.05 compared with the control value. ^e p < 0.01 compared with the control value. ^f p < 0.001 compared with the control value. “NT” means not tested.

Pterolinus I (**12**): colorless oil; $[\alpha]_D^{25} -30.7$ (c 0.10, EtOH); UV $\lambda_{\text{max}}^{\text{MeOH}}$ nm ($\log \epsilon$) 250 (3.86); CD $\epsilon_{315} -132.37$ (EtOH; c = 0.3 mg/mL); IR (neat) ν_{max} 3405, 2925, 1713, 16467 1510 cm^{-1} ; ^{13}C and ^1H NMR data, see Table 3; ESIMS m/z 333.02 $[\text{M} + \text{H}]^+$; HRESIMS m/z 333.1339 $[\text{M} + \text{H}]^+$ (calcd 333.1338 for $\text{C}_{18}\text{H}_{21}\text{O}_6$).

Pterolinus J (**13**): amorphous, white powder; $[\alpha]_D^{25} +11.6$ (c 0.10, EtOH); UV $\lambda_{\text{max}}^{\text{MeOH}}$ nm ($\log \epsilon$) 227 (4.10), 289 (3.83), 300 (3.76); CD $\epsilon_{320} -5.75$, $\epsilon_{309} -6.17$, $\Delta\epsilon_{257} -23.11$ (EtOH; c = 0.3 mg/mL); IR (neat) ν_{max} 3433, 2921, 1708, 1609, 1507 cm^{-1} ; ^{13}C and ^1H NMR data, see Table 3; ESIMS m/z 302.98 $[\text{M} + \text{H}]^+$; HRESIMS m/z 303.1233 $[\text{M} + \text{H}]^+$ (calcd 303.1232 for $\text{C}_{17}\text{H}_{19}\text{O}_5$).

In Vitro Cytotoxicity Assay. Fractions and isolates were tested against lung (A549), gingival (Ca9-22), breast (MEA-MB-231 and MCF7), and liver (HepG2 and Hep3B) cancer cell lines using established colorimetric MTT assay protocols.¹⁶ Doxorubicin was used as a positive control.

In Vitro Anti-inflammatory Assay. The assay procedure was performed as previously reported.^{17–19}

ASSOCIATED CONTENT

S Supporting Information. ^1H , ^{13}C NMR and HRMS data of all new compounds along with the stereochemical comparison of compounds **8**, **10**, **11**, and **15** are available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*Tel: +886-7-3121101, ext. 2162. Fax: +886-7-3114773. E-mail: aaronfrc@kmu.edu.tw (F.-R.C.). Tel: +886-4-22057153. Fax: +886-4-22060248. E-mail: yachwu@mail.cmu.edu.tw (Y.-C.W.).

ACKNOWLEDGMENT

This work was supported by grants from the National Science Council, Taiwan (NSC100-2917-I-037-002), and Department of Health, Executive Yuan, Taiwan (DOH99-TD-C-111-002). The authors deeply appreciate Dr. K.-H. Lee for the comments and suggestions, as well as the English revision by Dr. S. L. Morris-Natschke (Natural Products Research Laboratories, UNC).

REFERENCES

- (1) Parkash, E.; Sha Valli Khan, P. S.; Sreenivasa Rao, T. J. V.; Meru, E. S. *J. For. Res.* **2006**, *11*, 329–335.
- (2) Cho, J. Y.; Park, J.; Kim, P. S.; Yoo, E. S.; Baik, K. U.; Park, M. H. *Biol. Pharm. Bull.* **2001**, *24*, 167–171.
- (3) Kwon, H. J.; Hong, Y. K.; Kim, K. H.; Han, C. H.; Cho, S. H.; Choi, J. S.; Kim, B. W. *J. Ethnopharmacol.* **2006**, *105*, 229–234.
- (4) Kumar, N.; Ravindranath, B.; Seshadri, T. R. *Phytochemistry* **1974**, *13*, 633–636.
- (5) Krishnaveni, K. S.; Rao, J. V. *Phytochemistry* **2000**, *53*, 605–605.
- (6) Kesari, A. N.; Gupta, R. K.; Watal, G. *Phytochemistry* **2004**, *65*, 3125–3129.
- (7) Donnelly, B. J.; Donnelly, D. M. X.; O'Sullivan, A. M.; Prendergast, J. P. *Tetrahedron* **1969**, *25*, 4409–4414.
- (8) Donnelly, D. M. X.; O'Reilly, J.; Whalley, W. B. *Phytochemistry* **1975**, *13*, 2287–2290.
- (9) Muangnoicharoen, N.; Frahm, A. W. *Phytochemistry* **1981**, *20*, 291–293.
- (10) Juhász, L.; Szilágyi, L.; Antus, S.; Visy, J.; Zsila, F.; Simonyi, M. *Tetrahedron* **2002**, *58*, 4261–4265.
- (11) Muangnoicharoen, N.; Frahm, A. W. *Phytochemistry* **1982**, *21*, 767–727.
- (12) Awale, S.; Shrestha, S. P.; Tezuka, Y.; Ueda, J. Y.; Matsushige, K.; Kadota, S. *J. Nat. Prod.* **2005**, *68*, 858–864.
- (13) Eyton, W. B.; Ollis, W. D.; Sutherland, I. O. *Tetrahedron* **1966**, *21*, 2683–2696.
- (14) Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. *J. Biol. Chem.* **1994**, *269*, 5241–5248.
- (15) Yu, H. P.; Hsieh, P. W.; Chang, Y. J.; Chung, P. J.; Kuo, L. M.; Hwang, T. L. *Biochem. Pharmacol.* **2009**, *78*, 983–992.
- (16) Mosmann, T. *J. Immunol. Methods* **1983**, *65*, 55–63.
- (17) Yen, C. T.; Hwang, T. L.; Wu, Y. C.; Hsieh, P. W. *Eur. J. Med. Chem.* **2009**, *44*, 1933–1940.
- (18) Chang, H. L.; Chang, F. R.; Chen, J. S.; Wang, H. P.; Wu, Y. H.; Wang, C. C.; Wu, Y. C.; Hwang, T. L. *Eur. J. Pharmacol.* **2008**, *586*, 332–339.
- (19) Hwang, T. L.; Yen, S. H.; Leu, Y. L.; Chern, C. Y.; Hsu, H. C. *Br. J. Pharmacol.* **2006**, *48*, 78–87.